Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten van Smeden

Showing results (1-10 of 190) with videos related to

Pageof 19
Sort By:
Primer (Leawood, Kan.)|September 19, 2022
A Very Short List of Common Pitfalls in Research Design, Data Analysis, and ReportingMaarten van Smeden
Journal of Clinical Epidemiology|September 24, 2021
Causal analyses of existing databases: the importance of understanding what can be achieved with your data before analysis (commentary on Hernán)Tim P Morris, Maarten van Smeden
Thorax|November 16, 2021
QCOVID in Scotland: time to recalibrate our expectations?Rishi K Gupta, Maarten van Smeden
Nederlands Tijdschrift Voor Geneeskunde|March 15, 2023
[A new prognostic prediction model for heart failure: will it help the general practitioner?]Frans H Rutten, Maarten van Smeden
Nederlands Tijdschrift Voor Geneeskunde|March 29, 2023
[A new prognostic prediction model for heart failure: will it help the general practitioner?]Frans H Rutten, Maarten van Smeden
Journal of Clinical Epidemiology|April 30, 2018
Investigation of the "m" in the cmRCT (cohort multiple randomized controlled trial) design revealed dependence between trial resultsRolf H H Groenwold, Maarten van Smeden
Epidemiology (Cambridge, Mass.)|July 7, 2017
Efficient Sampling in Unmatched Case-Control Studies When the Total Number of Cases and Controls Is FixedRolf H H Groenwold, Maarten van Smeden
Statistics in Medicine|November 21, 2017
Event rate net reclassification index and the integrated discrimination improvement for studying incremental value of risk markersMaarten van Smeden, Karel G M Moons
Journal of Clinical Epidemiology|August 27, 2018
Comparability of treatment arms does not prevent correlated trial resultsRolf H H Groenwold, Maarten van Smeden
Epidemiology (Cambridge, Mass.)|October 16, 2020
Comment on Williamson et al. (OpenSAFELY): The Table 2 Fallacy in a Study of COVID-19 Mortality Risk FactorsDaniel Westreich, Jessie K Edwards, Maarten van Smeden
Pageof 19

Showing results (1-10 of 190) with videos related to

Sort By:
Pageof 19
Primer (Leawood, Kan.)|September 19, 2022
A Very Short List of Common Pitfalls in Research Design, Data Analysis, and ReportingMaarten van Smeden
Journal of Clinical Epidemiology|September 24, 2021
Causal analyses of existing databases: the importance of understanding what can be achieved with your data before analysis (commentary on Hernán)Tim P Morris, Maarten van Smeden
Thorax|November 16, 2021
QCOVID in Scotland: time to recalibrate our expectations?Rishi K Gupta, Maarten van Smeden
Nederlands Tijdschrift Voor Geneeskunde|March 15, 2023
[A new prognostic prediction model for heart failure: will it help the general practitioner?]Frans H Rutten, Maarten van Smeden
Nederlands Tijdschrift Voor Geneeskunde|March 29, 2023
[A new prognostic prediction model for heart failure: will it help the general practitioner?]Frans H Rutten, Maarten van Smeden
Journal of Clinical Epidemiology|April 30, 2018
Investigation of the "m" in the cmRCT (cohort multiple randomized controlled trial) design revealed dependence between trial resultsRolf H H Groenwold, Maarten van Smeden
Epidemiology (Cambridge, Mass.)|July 7, 2017
Efficient Sampling in Unmatched Case-Control Studies When the Total Number of Cases and Controls Is FixedRolf H H Groenwold, Maarten van Smeden
Statistics in Medicine|November 21, 2017
Event rate net reclassification index and the integrated discrimination improvement for studying incremental value of risk markersMaarten van Smeden, Karel G M Moons
Journal of Clinical Epidemiology|August 27, 2018
Comparability of treatment arms does not prevent correlated trial resultsRolf H H Groenwold, Maarten van Smeden
Epidemiology (Cambridge, Mass.)|October 16, 2020
Comment on Williamson et al. (OpenSAFELY): The Table 2 Fallacy in a Study of COVID-19 Mortality Risk FactorsDaniel Westreich, Jessie K Edwards, Maarten van Smeden
Pageof 19